Important Information for Applied Therapeutics, Inc. (APLT) Investors: Rosen Law Firm Announces Class Action Lawsuit and Lead Plaintiff Deadline
NEW YORK, Feb. 11, 2025 – Rosen Law Firm, a global investor rights law firm, alerts purchasers of securities of Applied Therapeutics, Inc. (APLT) between January 3, 2024, and December 2, 2024 (the “Class Period”), to take note of the important lead plaintiff deadline in the securities class action. The lawsuit alleges that Applied Therapeutics and certain of its top executives made false and misleading statements and failed to disclose material information to investors.
Background
Applied Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of various diseases. The company’s lead product candidate, ATI-501, is a small molecule inhibitor of the enzyme dihydropyrimidine dehydrogenase (DPD), which is being developed for the treatment of colorectal cancer and other solid tumors. The company has reported positive results from several clinical trials and has announced plans to initiate a pivotal Phase 3 clinical trial in the first half of 2025.
The Allegations
The complaint alleges that throughout the Class Period, defendants made materially false and misleading statements regarding the company’s business, operational and financial results. Specifically, the complaint alleges that defendants made false and/or misleading statements and/or failed to disclose that: (i) there were significant issues with the design, execution, and reporting of clinical trials for ATI-501, including concerns related to patient eligibility, data integrity, and adverse events; (ii) there were significant manufacturing issues with ATI-501, including issues related to the company’s ability to produce sufficient quantities of the drug for clinical trials and commercialization; and (iii) as a result of the foregoing, defendants’ positive statements about the company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Lead Plaintiff Deadline
If you purchased securities of Applied Therapeutics during the Class Period you may be entitled to compensation. The lead plaintiff deadline is February 18, 2025. The lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of the class. The lead plaintiff plays a significant role in directing the litigation and participates in key decision-making. You may also participate in the litigation without serving as the lead plaintiff. To obtain information about the lawsuit, contact Mark D. DeCicco of Rosen Law Firm at 212-671-1020 or by email at [email protected]. No Class has been certified. Yet.
Impact on Individuals
If you invested in Applied Therapeutics during the Class Period and believe that the company and its executives made false statements or failed to disclose material information, you may be able to recover your losses. The lead plaintiff deadline is February 18, 2025, so it is important to act quickly if you believe you may be entitled to compensation. Contact Rosen Law Firm to discuss your potential recovery.
Impact on the World
The impact of this class action lawsuit on the world at large may depend on the outcome of the litigation. If the allegations are proven true, it could lead to increased scrutiny of clinical trials and manufacturing processes in the biopharmaceutical industry, potentially resulting in increased transparency and accountability. It could also lead to financial losses for Applied Therapeutics and its shareholders, which could have ripple effects on the broader market. However, it is important to note that the outcome of the litigation is uncertain, and it is impossible to predict the exact impact on the world at this time.
Conclusion
Rosen Law Firm encourages investors who purchased securities of Applied Therapeutics during the Class Period to contact the firm before the lead plaintiff deadline on February 18, 2025, to discuss their potential recovery options. The firm represents investors worldwide, and it has a proven track record of successfully recovering damages for investors. For more information, please visit www.rosenlegal.com or contact Mark D. DeCicco at 212-671-1020 or by email at [email protected].
This notice is only a description of the lawsuit and should not be construed as legal advice or a solicitation to file a claim. The class has not yet been certified, and Rosen Law Firm is not acting as class counsel. The lead plaintiff has not yet been determined.
